We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
+3.21%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$340M
AUM Growth
-$182M
Cap. Flow
-$183M
Cap. Flow %
-53.98%
Top 10 Hldgs %
58.11%
Holding
39
New
6
Increased
3
Reduced
19
Closed
9

Top Buys

Rank Stock Value
1
ORKA
Oruka Therapeutics
ORKA
+$17.9M
2
PMN icon
ProMIS Neurosciences
PMN
+$4.17M
3
VRDN icon
Viridian Therapeutics
VRDN
+$4.09M
4
UNCY icon
Unicycive Therapeutics
UNCY
+$3.44M
5
RNAC icon
Cartesian Therapeutics
RNAC
+$3.12M

Top Sells

Rank Stock Value
1
URGN icon
UroGen Pharma
URGN
+$31.9M
2
ACLX
Arcellx
ACLX
+$26.1M
3
EOLS icon
Evolus
EOLS
+$17.9M
4
INSM icon
Insmed
INSM
+$16.8M
5
FOLD
Amicus Therapeutics
FOLD
+$14.8M

Sector Composition

Rank Sector Weight
1 Healthcare 97.54%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UNCY icon
26
Unicycive Therapeutics
UNCY
$137M
$3.49M 1.03%
+855,900
New +$3.44M
PMN icon
27
ProMIS Neurosciences
PMN
$123M
$3.49M 1.03%
+111,628
New +$4.17M
RNAC icon
28
Cartesian Therapeutics
RNAC
$229M
$3.22M 0.95%
+200,000
New +$3.12M
VTGN icon
29
VistaGen Therapeutics
VTGN
$9.89M
$2.03M 0.6%
674,075
-855,263
-56% -$2.92M
CLYM
30
Climb Bio
CLYM
$681M
$1.26M 0.37%
+248,168
New +$1.76M
ANAB icon
31
AnaptysBio
ANAB
$1.58B
– –
-25,000
Closed -$627K
ESPR
32
DELISTED
Esperion Therapeutics
ESPR
– –
-5,791,594
Closed -$12.9M
FOLD
33
DELISTED
Amicus Therapeutics
FOLD
– –
-1,495,500
Closed -$14.8M
INSM icon
34
Insmed
INSM
$21.4B
– –
-250,000
Closed -$16.8M
LXRX icon
35
Lexicon Pharmaceuticals
LXRX
$1.03B
– –
-30,000
Closed -$50.4K
PBYI icon
36
Puma Biotechnology
PBYI
$404M
– –
-1,486,544
Closed -$4.85M
SYRE icon
37
Spyre Therapeutics
SYRE
$8.54B
– –
-134,612
Closed -$3.16M
TERN
38
DELISTED
Terns Pharmaceuticals
TERN
– –
-1,149,406
Closed -$7.83M
KYTX icon
39
Kyverna Therapeutics
KYTX
$444M
– –
-499,152
Closed -$3.74M
1
2

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q3 2024 Portfolio in Review

As of Q3 2024, Great Point Partners held 39 positions worth $340M, down 35% from $522M the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Great Point Partners withdrew a net $183M in Q3 2024, closing 9 positions and reducing 19 holdings. Its most notable exit was Insmed, an estimated $16.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 100% a quarter earlier.

Against the trend, Great Point Partners opened a new position in Oruka Therapeutics worth $12.6M.

  • Great Point Partners's largest Q3 2024 buy was Oruka Therapeutics: 514,659 shares worth $12.6M.
  • Great Point Partners added most to Viridian Therapeutics in Q3 2024, an estimated $4.09M increase.
  • Great Point Partners's biggest Q3 2024 reduction was UroGen Pharma, cutting an estimated $31.9M.
  • Great Point Partners fully exited Insmed in Q3 2024, selling an estimated $16.8M.
  • Great Point Partners's ten largest holdings make up 58% of its $340M portfolio in Q3 2024.
  • Great Point Partners opened 6 new positions and closed 9 in Q3 2024.
  • Great Point Partners's portfolio value fell 35% quarter-over-quarter to $340M.

Based on Great Point Partners's 13F filing for Q3 2024, filed 13 Nov 2024.